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Dear Sir, We read the article titled "Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study" by Pellegrini et al. [1] with great interest. We have few suggestions and observations to make. It would be interesting to note the ocular surface status in these patients as short-term and long-term effects post botulinum toxin A (BTX-A) injection since the duration of the treatment in this study ranged from 1 to 17 years with a mean of 7.2 ± 5.4 years. Czyz et al. [2] in their study on Long-term Botulinum Toxin Treatment of Benign Essential Blepharospasm, Hemifacial Spasm, and Meige Syndrome concluded that the highest percentage of adverse events, both major and minor, occurred during the titration phase of treatment (treatment number 1-3). Similarly Defazio et al. [3] found adverse events in 14.2% of patients in the first year of treatment vs 3.4%in the tenth year of treatment which was also the observation made by Mejia et al. [4] in their study. It would rather be more interesting if the groups were divided based on number of injections as described in Table 1 .
Czyz et al. [2] in their study divided the groups based on number of treatments which comprised of initial treatment (treatment number 4 was taken as initial), treatment number 4 to final treatment and final treatment. Treatment number one to three was taken as control in their study. In present study it is not very clear that at what duration of treatment with BTX-A the eye is or how many botox injections were given to the eye when ocular surface parameters were recorded. The authors do acknowledge that the increased blink rate in hemifacial spasm may result in dysfunctional lubricity and blink-related microtrauma along with chronic ocular surface inflammation can itself affect the ocular surface status which also is proved in their table number 2 which compares the ocular surface parameters between the contralateral and homolateral. We suggest to take the controls as the patients of hemifacial spasm who presented for the first time in the study duration with no prior treatment or are at injection number 1 to <3. It is also well known that the effect of botulinum toxin is temporary and repeated applications are required. [5, 6] Gunes et al. [7] in their study on the corneal parameters and tear film in patients on botulinum toxin treatment prior to injection, 3 weeks and 3 months after the injection concluded that the Schirmer test score, corneal fluorescein staining values, and Ocular Surface Disease Index score were lower 3 weeks after injection but these values increased again by 3 months suggesting the short lived effect of injection. This is of particular importance because in current study the authors evaluated the ocular surface before and after one month of last botulinum toxin injection, so are they implying that the effect of the injection is cumulative on ocular surface status. Horwath-Winter et al. [6] investigated the effect of BTX-A injections on tear function and on the morphology of the ocular surface, found that the tear film break up time (TBUT) increased both 1 week and 1 month after the injections and no change in conjunctival cell morphology one month and 3 months after the injection. Botulinum toxin A has also been suggested for treating dry eye syndrome. [8] [9] [10] Sahlin et al. [11] in their study concluded that botulinum injection also leads to reduced lacrimal drainage after treatment. Additional lacrimal drainage test could have been performed in 11 of the 26 patients in the current study who were diagnosed as dry eyes using TFOS DEWS II criteria.
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Response to comments on: Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study
Dear Sir, First of all, we would like to thank you for the constructive comments [1] on our study on ocular surface status following botulinum A toxin. [2] The authors of the letter pointed out that since the adverse events of botulinum A toxin injection usually occur during the first period of treatment, it could be appropriate to divide our sample according to the number of injections received. Although we have already investigated the correlations between the ocular surface parameters and the duration of treatment, of course a further analysis based also on the number of injections may be of interest. The mean number of injections was 22.3 (range 2-53). The sample size was too small to create 3 different subgroups according to the number of injections, as suggested (6-12; 12-25; >25). Furthermore, we were also unable to create a control group with patients who received a number of injections comprised between 1 and 3, because they were only 4. Therefore, we divided overall patients into 2 groups: Those who received less than 25 injections (n = 14) and those who received 25 or more injections (n = 12). Tear osmolarity was significantly lower in patients who received less than 25 injections (291.6 ± 22.7 vs 309.3 ± 9.9 mOsm/L, P = 0.017). This result is in agreement with the correlation between tear osmolarity and the duration of treatment already found in our study. Conversely, we did not find any significant difference for tear film break-up time, Schirmer test, corneal sensitivity, corneal staining, and OSDI score between the two groups (all P > 0.05).
In conclusion, the relationship between the number of botulinum A toxin injections and the ocular surface changes is not fully clarified by our study and further prospective studies with larger sample size are required to elucidate this issue. The evaluation of other ocular surface parameters not investigated in this paper, such as Jones test, could provide further useful information.
